Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ASCEND: Higher Dose Nusinersen in SMA Patients Previously Treated With Risdiplam
NCT05067790Phase 3Active, not recruiting
- Sponsor
- Biogen
- Start
- Jan 2022
- Primary completion
- Sep 2027
- Modality
- Modified DNA Oligonucleotides, Single-strand DNA, Antisense Oligonucleotides (ASOs)
- Countries
- 5
01
Overview
A Phase 3 trial of nusinersen in spinal muscular atrophy (SMA), sponsored by Biogen. Started Jan 2022; status: active, not recruiting.
02
Drugs
nusinersen
03
Conditions
spinal muscular atrophy (SMA)
Beyond the preview
Go deeper on NCT05067790.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05067790.